Tarsus Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tarsus Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $451.36M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $182.95M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $17.45M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $25.82M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $57.03M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 14, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($66.42M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($115.55M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($135.89M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($62.09M) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | ($13.83M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($26.81M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($4.67M) | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | ($1.32M) | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.97M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($120.57M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($143.16M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($62.71M) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | ($12.16M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($27.00M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($4.30M) | Mar 31, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.32M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $53.39M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $50.31M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $42.62M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $41.71M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $18.83M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $3.16M | Mar 31, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $427.32M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $237.31M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $108.70M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $44.95M | Feb 25, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.45M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($83.03M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($117.49M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($49.03M) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $3.75M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($21.14M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($3.67M) | Mar 31, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.86M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.57M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $1.50M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $506.0K | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $586.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $456.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $175.0K | Mar 31, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $562.16M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $376.99M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $265.49M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $227.86M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $178.91M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $171.97M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $58.32M | Mar 31, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $218.73M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $152.46M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $68.50M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $34.96M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $12.18M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.99M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $919.0K | Mar 31, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.43M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $224.53M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $196.99M | Feb 23, 2026 |
| FY2025 | Dec 31, 2022 | $192.90M | Feb 23, 2026 |
| FY2024 | Dec 31, 2021 | $166.73M | Feb 25, 2025 |
| FY2022 | Dec 31, 2020 | $165.98M | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | ($6.01M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | ($1.35M) | Mar 31, 2021 |
| FY2020 | Dec 31, 2017 | ($44.0K) | Mar 31, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($426.63M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($360.21M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($244.66M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($108.76M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($46.67M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($32.85M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($6.03M) | Mar 31, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.64M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $94.82M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $224.95M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $71.66M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $171.33M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $168.13M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $57.95M | Mar 31, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.44M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $71.85M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $29.82M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $19.43M | Feb 27, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | (4) | Mar 14, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | (4) | Mar 14, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.55M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 38.35M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 34.21M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 26.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 20.70M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 20.32M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 2.65M | Mar 31, 2021 |